Skip to content

Staar Surgical STAA Royalty income

Royalty income at other companies

Lightwave Logic, Inc. logo
Lightwave Logic, Inc.LWLG
$50K
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$12K
Carter's logo
Carter'sCRI
$4.53M-6.0%
Helix Energy Solutions Group logo
Helix Energy Solutions GroupHLX
$1.69M+19.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$4.18M+5.8%
Pfizer logo
PfizerPFE
$396M+28.6%

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%
Free cash flow-$22.1M-207%

Valuation

See full
Market cap$1.44B+77.9%
Enterprise value$1.35B+100.0%
P/S+2.1×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Reported directly by Staar Surgical in its filing.

Tagged under the XBRL concept us-gaap:RoyaltyIncomeNonoperating.

The official record: Staar Surgical’s 10-Q, filed May 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Staar Surgical's royalty income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Staar Surgical's royalty income?
Staar Surgical (STAA) reported royalty income of $508K in Q1 2024.
What does royalty income mean?
This metric represents revenue generated from licensing intellectual property, patents, or proprietary technology to third parties. It serves as a source of high-margin, non-core income that leverages the company's existing research and development investments. Consistent growth in this area indicates strong market demand for the company's technological innovations and effective monetization of its patent portfolio.